AGP Picks
View all

Imfinzi market projected to reach $5.11 million by 2030

Nov. 5, 2026
Imfinzi market projected to reach $5.11 million by 2030
By AI, Created 00:30 UTC, Nov 05, 2026, AGP -

The Business Research Company says the global Imfinzi (durvalumab) market will grow from $3.01 million in 2025 to $5.11 million by 2030, driven by rising cancer cases, broader immunotherapy use and more personalized treatment approaches. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Imfinzi’s growth tracks the wider expansion of cancer immunotherapy, a treatment area gaining traction as cancer diagnoses rise worldwide. - The market outlook points to continued demand for PD-L1 inhibitors in lung cancer and other solid tumors. - The report also signals growing commercial interest in personalized medicine and combination regimens.

What happened: - The Business Research Company released its Imfinzi (durvalumab) Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report forecasts the Imfinzi market will rise from $3.01 million in 2025 to $3.36 million in 2026. - The report projects the market will reach $5.11 million by 2030. - The company estimates 11.4% CAGR growth from 2025 to 2026 and 11.1% CAGR growth through 2030. - North America held the largest regional share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

The details: - Imfinzi, also known as durvalumab, is a human monoclonal antibody immunotherapy. - The drug blocks programmed death-ligand 1, or PD-L1, which tumors use to evade immune detection. - Imfinzi is approved for non-small cell lung cancer, small cell lung cancer, biliary tract cancer and advanced urothelial carcinoma. - The report links recent market growth to the clinical effectiveness of immune checkpoint inhibitors, rising lung cancer prevalence, regulatory approvals in oncology, improved patient survival and pharmaceutical investment. - The report says future growth will be supported by new cancer indications for durvalumab, broader access to immunotherapy, more oncology trials, higher oncology spending and combination treatment progress. - Key trends cited in the report include wider use of PD-L1 inhibitors, greater immunotherapy adoption in lung cancer, growth in combination immuno-oncology regimens, biomarker-driven therapies and expanded use across solid tumors. - Rising cancer incidence remains a major demand driver. - The National Cancer Institute reported in May 2024 that the U.S. had 18.1 million cancer survivors in 2022 and projected that number would reach 22.5 million by 2032. - The report ties the cancer burden to aging populations and lifestyle factors including smoking, poor diet and obesity. - Personalized medicine is another growth driver cited in the report. - The Personalized Medicine Coalition said 34% of FDA-approved new drugs in 2022 were personalized medicines. - The coalition also said at least 25% of new drugs each year over the previous eight years fell into that category. - The report says Imfinzi fits personalized treatment because it targets PD-L1 and can be matched to tumor biology and immune profiles. - The report includes updated graphics and tables, market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and key technology and future trend analysis.

Between the lines: - The market size remains small in absolute dollar terms, but the double-digit growth rate suggests durable momentum in oncology immunotherapy. - The mix of drivers points to a market shaped more by treatment expansion and sequencing than by a single product cycle. - North America’s lead and Asia-Pacific’s growth outlook suggest established uptake in one market and faster expansion in another.

What's next: - The report expects growth to continue as durvalumab gains new indications and as combination regimens become more common. - Broader use of biomarker-based and personalized cancer treatment could further expand the addressable market. - The company has also added new 2026 report features, including hotspot infographics, TAM analysis and forecasting dashboards.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Latin American Newswire

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Latin American Newswire

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.